Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions.

Kleynerman, Annie; Rybova, Jitka; Faber, Mary L; McKillop, William M; Levade, Thierry; Medin, Jeffrey A

Kleynerman, Annie; Rybova, Jitka; Faber, Mary L; McKillop, William M; Levade, Thierry; Medin, Jeffrey A.

Afiliación

Kleynerman A; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Rybova J; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Faber ML; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
McKillop WM; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Levade T; Laboratoire de Biochimie Métabolique, CHU Toulouse, and INSERM U1037, Centre de Recherches en Cancérologie de Toulouse, Université Paul Sabatier, 31062 Toulouse, France.
Medin JA; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

Biomolecules ; 13(2)2023 02 01.

Article en En | MEDLINE | ID: mdl-36830643

Asunto(s)

Lipogranulomatosis de Farber; Atrofia Muscular Espinal; Epilepsias Mioclónicas Progresivas; Ratones; Animales; Humanos; Lipogranulomatosis de Farber/genética; Ceramidas; Epilepsias Mioclónicas Progresivas/genética; Atrofia Muscular Espinal/genética; Mutación

Palabras clave

Farber disease; SMA-PME; acid ceramidase; ceramide; lipogranulomatosis; lysosomal storage disorder

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Atrofia Muscular Espinal / Epilepsias Mioclónicas Progresivas / Lipogranulomatosis de Farber Límite: Animals / Humans Idioma: En Revista: Biomolecules Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google